Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education
Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...
Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment
Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...
Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations
Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...
Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals
Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...
Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices
Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly...
Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...
3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...
3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...
Amgen to Establish New Site in Hyderabad, India, with Focus on Technology and Digital Innovation
Amgen (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has announced strategic plans...
MSD to Acquire Curon Biopharmaceutical’s CD3 x CD19 Bispecific Antibody CN201 in USD 1.3 Billion Deal
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic acquisition agreement with Shanghai-based...
Sichuan Huiyu Pharmaceutical’s Chairman Ding Zhao Faces CSRC Investigation for Short-Term Stock Trading
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its...
Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion...
Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...